X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (857) 857
high-dose interleukin-2 (705) 705
oncology (639) 639
immunotherapy (400) 400
female (345) 345
index medicus (330) 330
male (292) 292
middle aged (266) 266
immunology (263) 263
cancer (251) 251
adult (246) 246
recombinant interleukin-2 (234) 234
interleukin-2 - therapeutic use (206) 206
interleukin-2 (205) 205
activated killer-cells (197) 197
animals (197) 197
hematology (189) 189
aged (188) 188
high-dose chemotherapy (161) 161
melanoma (156) 156
treatment outcome (153) 153
antineoplastic combined chemotherapy protocols - therapeutic use (141) 141
combined modality therapy (140) 140
medicine, research & experimental (140) 140
care and treatment (134) 134
therapy (132) 132
tumor-infiltrating lymphocytes (132) 132
chemotherapy (131) 131
metastatic melanoma (130) 130
antineoplastic agents - therapeutic use (128) 128
phase-ii trial (126) 126
interleukin-2 - administration & dosage (124) 124
colony-stimulating factor (121) 121
neoplasms - therapy (119) 119
interferon-alpha (113) 113
transplantation (112) 112
prognosis (107) 107
adoptive immunotherapy (105) 105
carcinoma, renal cell - therapy (105) 105
advanced cancer (104) 104
interleukin-2 - adverse effects (102) 102
kidney neoplasms - therapy (102) 102
immunotherapy - methods (101) 101
bone-marrow transplantation (95) 95
mice (95) 95
melanoma - therapy (91) 91
cytokines (88) 88
health aspects (88) 88
pharmacology & pharmacy (85) 85
renal cell carcinoma (85) 85
activated killer cells (84) 84
survival (81) 81
clinical trials as topic (80) 80
research (80) 80
lymphocytes (79) 79
melanoma - drug therapy (77) 77
neoplasms - immunology (76) 76
carcinoma, renal cell - drug therapy (75) 75
kidney neoplasms - pathology (75) 75
adolescent (74) 74
kidney neoplasms - drug therapy (71) 71
renal-cell carcinoma (71) 71
survival rate (71) 71
neoplasm metastasis (70) 70
transplantation, autologous (70) 70
surgery (69) 69
metastasis (67) 67
phase-ii (67) 67
bone-marrow-transplantation (66) 66
medicine & public health (66) 66
interleukin-2 - pharmacology (65) 65
neoplasm staging (65) 65
hematopoietic stem cell transplantation (64) 64
survival analysis (64) 64
cancer-patients (62) 62
interferon (62) 62
t-cells (61) 61
tumor-necrosis-factor (60) 60
child (58) 58
phase-iii trial (58) 58
regulatory t-cells (58) 58
carcinoma, renal cell (57) 57
interferon-alpha - therapeutic use (56) 56
kidney neoplasms - immunology (56) 56
melanoma - immunology (56) 56
stem-cell transplantation (56) 56
carcinoma, renal cell - immunology (55) 55
il-2 (55) 55
immunotherapy, adoptive (55) 55
disease-free survival (52) 52
non-hodgkins-lymphoma (52) 52
t-lymphocytes - immunology (52) 52
tumors (52) 52
carcinoma, renal cell - secondary (51) 51
melanoma - secondary (51) 51
killer cells, natural - immunology (50) 50
recombinant human interleukin-2 (50) 50
antibodies, monoclonal - therapeutic use (49) 49
biotechnology & applied microbiology (48) 48
cancer vaccines - therapeutic use (48) 48
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0179431
Cytokines are potent immune modulating agents but are not ideal medicines in their natural form due to their short half-life and pleiotropic systemic effects.... 
LIGAND-BINDING | ALPHA-RECEPTOR | MULTIDISCIPLINARY SCIENCES | LONG-TERM SAFETY | COMPLEXES | REGULATORY T-CELLS | MODULATION THERAPIES | IL-2 | CYTOKINE | HIGH-DOSE INTERLEUKIN-2 | RENAL-CELL CARCINOMA | Neoplasms - metabolism | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Interleukin-2 Receptor beta Subunit - metabolism | Interleukin Receptor Common gamma Subunit - metabolism | Transplantation, Homologous | T-Lymphocytes, Regulatory - immunology | STAT5 Transcription Factor - metabolism | Neoplasms - therapy | Interleukin Receptor Common gamma Subunit - agonists | CD8-Positive T-Lymphocytes - metabolism | Female | Interleukin-2 - analogs & derivatives | Phosphorylation - drug effects | Polyethylene Glycols - pharmacology | Models, Theoretical | Tumor Microenvironment - drug effects | Interleukin-2 - pharmacokinetics | Interleukin-2 Receptor beta Subunit - agonists | Mice, Inbred C57BL | Polyethylene Glycols - pharmacokinetics | Receptors, Interleukin-2 - metabolism | Mice, Inbred C3H | Tumor Microenvironment - immunology | T-Lymphocytes, Regulatory - drug effects | Algorithms | Animals | Interleukin-2 Receptor alpha Subunit - agonists | Interleukin-2 Receptor alpha Subunit - metabolism | Prodrugs - pharmacokinetics | Neoplasms - immunology | CD8-Positive T-Lymphocytes - drug effects | Cell Line, Tumor | Drug Liberation | Interleukin-2 - pharmacology | Mice, Inbred BALB C | Kinetics | CD8-Positive T-Lymphocytes - immunology | Prodrugs - pharmacology | Receptors, Interleukin-2 - agonists | Physiological aspects | Care and treatment | Interleukin-2 | Immunotherapy | Patient outcomes | Cancer | Polyethylenes | Conjugates | CD8 antigen | Interleukin | Lymphocytes T | Anticancer properties | Proteins | Biological effects | Cell activation | Immunology | Interleukin 2 | Lymphocytes | Polyethylene glycol | Modelling | Drug dosages | Immune system | Interleukin 2 receptors | Pharmacodynamics | Cytokines | Immunoregulation | Melanoma | Radioactive half-life | Pharmacology | Affinity | Ligands | Mutation | Pharmacokinetics | In vitro methods and tests | Tumors
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2010, Volume 107, Issue 26, pp. 11906 - 11911
IL-2 immunotherapy is an attractive treatment option for certain metastatic cancers. However, administration of IL-2 to patients can lead, by ill-defined... 
Receptors | Lungs | Cell lines | Melanoma | Cellular immunity | Mice | Natural killer cells | Pulmonary edema | Endothelial cells | Tumors | Tumor | T cell | Cytokine/mAb complexes | Cytokine | NK cell | cytokine | IMMUNE-COMPLEXES | MULTIDISCIPLINARY SCIENCES | ANTIBODY | ALPHA | TOXICITY | RENAL-CANCER | tumor | cytokine/mAb complexes | IN-VIVO | BIOLOGICAL-ACTIVITY | REGULATORY T-CELLS | HIGH-DOSE INTERLEUKIN-2 | CD8(+) CELLS | Recombinant Proteins - therapeutic use | Immunotherapy - methods | Interleukin-2 - adverse effects | Homeodomain Proteins - metabolism | Humans | Interleukin-2 - therapeutic use | Interleukin-2 - antagonists & inhibitors | Recombinant Proteins - adverse effects | Lung - cytology | Pulmonary Edema - etiology | Interleukin-2 Receptor alpha Subunit - genetics | Lymphocytes - immunology | Melanoma, Experimental - immunology | Lung Neoplasms - secondary | Interleukin-2 - administration & dosage | Melanoma, Experimental - secondary | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - deficiency | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Receptors, Interleukin-2 - metabolism | Lung Neoplasms - therapy | Homeodomain Proteins - genetics | Recombinant Proteins - administration & dosage | Immunotherapy - adverse effects | Mice, Knockout | Endothelial Cells - immunology | Lung Neoplasms - immunology | Animals | Interleukin-2 Receptor alpha Subunit - metabolism | Antibodies, Monoclonal - administration & dosage | Pulmonary Edema - immunology | Antigen-Antibody Complex - administration & dosage | Antigen-Antibody Complex - immunology | Lung - immunology | Care and treatment | Interleukin-2 | Health aspects | Immunotherapy | Methods | Biological Sciences | mAb complexes
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 04/2019, Volume 30, Issue 4, pp. 402 - 409
The US Food and Drug Association has approved interferon-α (IFN-α) and interleukin-2 (IL-2) as adjuvant therapy in malignant melanoma. The objective of the... 
melanocytic tumor | interleukin-2 | brain metastasis | malignant melanoma | interferon-α | thrombocytopenia | EFFICACY | PHASE-II | ADJUVANT THERAPY | METASTATIC MELANOMA | ONCOLOGY | I INTERFERONS | HIGH-DOSE INTERFERON-ALPHA-2B | interferon-alpha | PHARMACOLOGY & PHARMACY | Clinical Reports
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2016, Volume 22, Issue 3, pp. 680 - 690
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 1991, Volume 9, Issue 4, pp. 694 - 704
Because of the ability of interleukin-2 (IL-2) to support the proliferation and activation of numerous types of immunocompetent cells and to support the... 
VASCULAR LEAK SYNDROME | HUMAN-LYMPHOCYTES | CANCER-PATIENTS | COLONY-STIMULATING FACTOR | CLINICAL-TRIAL | ONCOLOGY | TUMOR NECROSIS FACTOR | ENDOTHELIAL-CELLS | RECOMBINANT INTERLEUKIN-2 | ACTIVATED KILLER CELLS | HIGH-DOSE INTERLEUKIN-2 | Capillary Permeability - drug effects | Interleukin-2 - adverse effects | Humans | Syndrome
Journal Article
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 12/2009, Volume 1182, Issue 1, pp. 14 - 27
The development of biologic therapies for patients with cancer has in part been impeded by the extraordinary complexity and intrinsic feedback mechanisms... 
chloroquine | cancer | autophagy | biologic therapy | HMGB1 | interleuken-2 | Autophagy | Interleuken-2 | Chloroquine | Biologic therapy | Cancer | HALF-LIFE | CARBONIC-ANHYDRASE-IX | MULTIDISCIPLINARY SCIENCES | RECOMBINANT INTERLEUKIN-2 | RENAL-CELL CARCINOMA | METASTATIC MELANOMA | IN-VIVO | HIGH-DOSE INTERLEUKIN-2 | PURIFIED HUMAN INTERLEUKIN-2 | ADOPTIVE IMMUNOTHERAPY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 7, pp. 2039 - 2047
Journal Article
ACTA ONCOLOGICA, ISSN 0284-186X, 2018, Volume 57, Issue 5, pp. 589 - 594
Background: Interleukin-2 (IL2)-based immunotherapy is curative for a small subset of patients with metastatic renal-cell carcinoma (mRCC). Preclinical data... 
SURVIVAL | THERAPY | SOLID TUMORS | EVEROLIMUS | ONCOLOGY | TEMSIROLIMUS | SUNITINIB | ALPHA | HIGH-DOSE INTERLEUKIN-2 | COMBINATION | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Journal Article